A child is examined by a doctor

Key facts

AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company.

Our mission is to make a meaningful difference to patient health through great medicines that bring benefit for patients and add value for our stakeholders and society.

We discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.

We also work with others to combine complementary skills and strengthen the platform for success in meeting a common goal: improved healthcare.

We are active in over 100 countries with a growing presence in emerging markets including China, Brazil, Mexico and Russia.

We employ over 61,000 people (46% in Europe, 24% in the North America, 7% in Latin America and 24% in Asia, Africa and Australasia).

We invest over $4 billion in R&D each year. Around 15,7001 people work in our R&D organisation and we have 14 major R&D centres in eight countries, including Sweden, the US and the UK.

We have 9,300 employees at 23 supply and manufacturing sites in 16 countries.

In 2010, our worldwide sales totalled over $33 billion (including 10 medicines with sales of over $1 billion each).

Alongside our commitment to competitiveness and performance, we continue to be led by our core values to deliver business success responsibly. We are positioned in the top 8% in the sector in the Dow Jones World and STOXX (European) Sustainability Indexes.


1 including MedImmune

 

 Non-communicable diseases are a global problem which account for some 36 million deaths every year


The increasing burden of NCDs in low and middle-income countries poses an economic, social and moral stumbling block to global health and prosperity. This underscores the importance of partnership to understand what the most significant problems are and to work together to solve them.

David Brennan

IFPMA President, AstraZeneca Chief Executive Officer